Introduction
============

Since the discovery of penicillin by Alexander Fleming produced by the filamentous fungus *Penicillium notatum*, the genus *Penicillium* has been deeply studied for its capacity to produce a wide range of natural products (NPs) (secondary metabolites), many of them with biotechnological and pharmaceutical applications. *P. chrysogenum* (recently renamed as *P. rubens*) is the most relevant member of more than 354 *Penicillium* species that constitute the genus ([@B143]). *Penicillium* is usually found in indoor environments and associated with food spoilage. It is known as an industrial producer of β-lactam antibiotic in particularly penicillin, and current production strains result from several decades of classical strain improvement (CSI) ([@B78]; [@B91]). The CSI program began in 1943 with the isolation of *P. chrysogenum* NRRL 1951 capable of growing in submerged cultures. This strain was subjected to a long serial process of mutations induced by 275 nm ultraviolet and X-ray irradiation, nitrogen mustard gas and nitroso-methyl guanidine exposure, single spore selection and selection for loss of pigments, improved growth in large scale industrial fermenters and enhanced levels of penicillin production. CSI programs were developed in several companies ([@B13]), and this has resulted in an increase of penicillin titers by at least three orders of magnitude ([@B199]). As consequence, numerous genetic modifications were introduced in *P. chrysogenum*. Some have been studied in detail, most notably the amplification of the penicillin biosynthetic clusters and DNA inversions in this region ([@B69], [@B70]; [@B13]). Although the CSI had a major impact on the production of β-lactams by *P. chrysogenum*, it also affected secondary metabolism in general. Indeed, a proteome analysis performed between *P. chrysogenum* NRRL 1951 and two derived strains (Wisconsin 54-1255 and AS-P-78) showed reduced levels of proteins related to secondary metabolism in the higher penicillin producer strains ([@B96]). Genome sequencing of *P. chrysogenum* Wisconsin 54-1255 revealed the presence of several secondary metabolite encoding biosynthetic gene clusters (BGCs) in addition to the penicillin cluster, most of which have only be poorly studied and remain to be characterized (Figure [1](#F1){ref-type="fig"}). The products of the BGCs are either nonribosomal peptides (NRPs), polyketides (PKs) or hybrid molecules.

![Chromosomal localization of known and predicted PKS and NRPS genes and representative structures of associated secondary metabolites identified in *Penicillium chrysogenum*. Chromosomal localization of PKS and NRPS genes. Blue and red lines indicate known and unknown associated products so far, respectively.](fmicb-09-02768-g001){#F1}

*Penicillium chrysogenum* produces a broad range of secondary metabolites such as roquefortines, fungisporin (a cyclic hydrophobic tetrapeptide), siderophores, penitric acid, ω-hydroxyemodin, chrysogenin, chrysogine, sesquiterpene PR-toxin and sorbicillinoids, but likely also possesses the ability to produce other compounds not detected before. For most of the identified compounds, the responsible BGCs are unknown. The development of new bioinformatics tools (SMURF, AntiSMASH) ([@B106]; [@B213]; [@B21]) and the increase in the number of fungal genomes sequenced to date has opened the possibility to discover new NPs with novel properties (genome mining). The genes involved in the biosynthesis, regulation and transport of secondary metabolites tend to be arranged in the genome in clusters. Importantly, these gene clusters include the core biosynthetic genes which either encode polyketide synthases (PKSs), nonribosomal peptide synthetases (NRPSs) or terpene synthases genes ([@B183]). Recently, a global analysis was performed on 24 genomes of *Penicillium* species and this identified 1,317 putative BGCs predominated by two classes based on PKS (467) and NRPS (260) ([@B143]). In *P. chrysogenum* there are 33 core genes in the secondary metabolism that encode 10 NRPS, 20 PKS, 2 hybrid NRPS--PKS, and 1 dimethyl-allyl-tryptophan synthase ([@B200]; [@B106]; [@B131]; [@B172]) (Figure [1](#F1){ref-type="fig"}). A large number of PKS and NRPS enzymes are found also in other *Penicillium* species but only part of these gene clusters are shared, which suggests an unexplored potential of the secondary metabolome even in a single genus.

Here, we summarize the most recent strategies for engineering filamentous fungi with particular attention to *P. chrysogenum*, a promising cell factory of novel products with new application spectra. A brief description of the key biosynthetic enzymes involved in biosynthesis of secondary metabolites in fungi is provided.

The Building Enzymes of the Natural Products
============================================

Nonribosomal peptide synthetases are large, highly structured and complex enzymatic machineries, closely related to other modular enzymes such as PKSs, NRPS--PKS hybrid synthetases and fatty acid synthetases (FASs). They have certain distinct properties in common, the most striking one being their structural division in domains and modules, which is manifested in their shared evolutionary history ([@B184]). Every enzyme minimally consists of one module, a functionally distinct unit, which allows for the recruitment and subsequent incorporation of a precursor into a growing product. Domains as well as modules are clearly defined and evolutionary exchangeable structures amongst multi-modular enzymes. In the case of PKS and NRPS, this led to the occurrence of a variety of NRPS--PKS hybrids ([@B61]; [@B180]; [@B116]; [@B144]).

Nonribosomal Peptides (NRPs) and Nonribosomal Peptide Synthetases (NRPSs)
-------------------------------------------------------------------------

In comparison to most ribosomally derived peptides, NRPs are low molecular weight products. The structural diversity of NRPs is tremendous, mostly due to their chemical complexity. Significantly contributing to this diversity is the fact that NRPS are not only reliant on proteinogenic amino acids, but up until now more than 500 substrates were identified, which serve as NRPS building blocks ([@B34]). These molecules are predominantly amino acids, but not exclusively, since fatty acids, carboxylic acids and others substrates have been reported in NRPs ([@B125]). NRP thus represent a diverse group of natural compounds and occur as linear, branched, circular or macrocircular structures ([@B52]; [@B194]). The natural functions of NRPs are as diverse as their structures. Signaling, communication, metal-ion chelation, host protection are important functions performed by NRPs, though many compounds are not yet fully characterized in this respect. Nevertheless, the characterization of NPs for applied purposes is well developed and led to a vast collection of ground-breaking pharmaceuticals, including antibiotics, anti-fungal agents, immunosuppressants as well as cytostatic drugs ([@B73]; [@B208]; [@B52]).

Structurally, every NRPS module, initiation (1), elongation (n) or termination (1), requires a minimal set of domains (Figure [2A](#F2){ref-type="fig"}) ([@B187]). The two domains essential to every module are the adenylation domain (A) and the non-catalytic thiolation domain (T). This tandem di-domain enables the specific selection and activation of a given substrate. However, the T-domain must first go through 4′-phosphopantetheinyl transferase (PPTase) and coenzyme A (CoA) dependent activation after expression, by transferring the phosphopantetheine moiety of CoA onto a conserved serine residue, in order to enter the holo state. Also, adenylation domains (A) have accompanying factors, or proteins, called MbtH-like proteins (MLPs) ([@B158]; [@B11]). In contrast to PPTases, MLPs are merely interacting with the A-domain, however, they do not have an intrinsic enzymatic activity, but rather a chaperoning function upon binding a distinct part of the A domain ([@B67]; [@B136]; [@B177]). In addition to these domains, any elongation module will require a condensation domain (C), which connects two modules and links up- and downstream activated substrates via a peptide bond. C-domains are stereospecific for both, up- and downstream activated substrates and render the resulting intermediate compound attached to the downstream T-domain. Lastly, the C-terminal termination module essentially requires a thioesterase domain (Te), to catalytically release the covalently bound compound of the NRPS, returning the NRPS complex to the ground state for another reaction cycle. In addition to these essential domains, we can distinguish a series of additional domains, performing epimerization, halogenation, cyclization, macrocyclization, multimerization or methylation ([@B7]; [@B90]; [@B22]).

![**(A)** Nonribosomal peptide synthetases (NRPSs) and **(B)** polyketide synthase (PKS) minimal domain structure. For details see the text. C, condensation domain; PCP, peptidyl carrier protein; A, adenylation domain; E, epimerase; MT, methyltransferase; PPT, 4'-phosphopantetheine transferase domain; Oxy, oxygenation domain; Cy, cyclization domain; ACP, acyl carrier protein; AT, acyltransferase domain; KS, ketosynthase domain; KR, ketoreductase domain; DH, dehydratase domain; ER, enoyl reductase domain; Te, thioesterase domain.](fmicb-09-02768-g002){#F2}

Theses enzymatic machineries can be classified as *type I NRPS* when the modules are arranged on a single protein, while the *type II NRPS* are independent proteins in an transient manner during the NRP synthesis ([@B174]; [@B92]). A NRPS can be as simple as a single modular unit containing three domains, although the most complex and largest structure known contains 15 modules with 46 domains ([@B205]; [@B24]) yielding a 1.8 MDa protein complex (type I NRPS). Although the size of a NRPS, as well as the modular sequence, limits the setup of the resulting NRP, it is common that NRPS cluster and interact with tailoring enzymes in order to produce products of a higher complexity ([@B224]). To enable such specific interactions, NRPS can contain small stretches of up to 30 amino acids at the C- or N-terminus, which form a rather specific recognition point, thus enabling communication (COM-domain) between multiple NRPS of one cluster (type II NRPS) ([@B82]; [@B59]). To date three types of NRPS system have been described according to their synthesis mode (or strategy of biosynthesis): Type A (linear), type B (iterative) and type C (non-linear) (Figure [3](#F3){ref-type="fig"}). The ***type A system*** harbors the typical domain organization A-T(C-A-T)~n-1~-Te/C, where n represents the number of amino acids in the peptide. In this linear NRPS, the order and number of modules correlates with the amino acid sequence in the NRP and thus it is possible to predict the product that will be formed. Usually, in fungal NRPSs the cyclisation reaction is performed by a specialized C domain instead of Te domain. Since each module catalyzes one cycle during the chain elongation of the nascent NRP due to its specific activity, this system is considered analogous to type I PKS. In fungi, the most prominent examples of this type of NRPS are ACV synthetases (β-lactams), cyclosporin synthetases (Cyclosporin A) and peptaibol synthetases (peptaboils, a class of antibiotics with a high content of α-aminoisobutyric acid) ([@B217]; [@B195]; [@B68]; [@B65]). The ***type B system*** is characterized to employ all their modules or domains more than once during the synthesis of a single NRP, which enables the assembling of peptide chains that contain repeated sequences along the structure ([@B138]). An example of this mode of synthesis occurs in *Fusarium scirpi* during the biosynthesis of enniatin (antibiotic), which is achieved through the repeated use of two modules. Other examples of type B NRPSs are the siderophore synthetases, which only contain three A domains that catalyze the biosynthesis of ferrichrome ([@B138]; [@B65]). In ***type C system***, the non-linear NRPSs have at least one domain conformation that deviate from (C-A-T)~n-1~ organization contained in linear NRPSs. Likewise, in these synthetases the module arrangement does not correspond to the amino acid sequence in the NRP. Unlike type A NRPS, in type C NRPSs the non-linear peptide is produced by a branch-point synthase and contains uncommon cyclization patterns. Another important difference is that non-linear NRPSs can incorporate small soluble structures, such as amines into the rising NRP through specialized C domains ([@B195]; [@B68]; [@B92]). Capreomycin, bleomycin and vibriobactin are examples of NRPs produced by this type of synthetases ([@B68]). In continuation, a brief description of the main NRPS domains features is provided.

![Mode of biosynthesis of nonribosomal peptide synthetases. For details see the text. C, condensation domain; PCP, peptidyl carrier protein; A, adenylation domain; E, epimerase; MT, methyltransferase; Te, thioesterase domain; Cy, cyclization domain.](fmicb-09-02768-g003){#F3}

### Adenylation (A) and Thiolation (T) Domains

Any NRPS module minimally consists of an A- and T-domain (or peptidyl carrier protein, PCP), enabling single module functionality and multi-modular functionality upon addition of C domains ([@B118]; [@B18]; [@B68]; [@B108]; [@B22]). They are often referred to as "gatekeeper" domains, as there is no subsequent product formation without prior adenylation and thioesterification of a substrate ([@B192]). The two core functions of the A-domain are characterized first, through the hydrolysis of ATP or adenylation, allowing an AMP-substrate conjugate to be formed, which is subsequently transferred to the free thiol group of the 4′-phosphopantetheinyl-moiety (Ppant), which is anchored to a conserved serine residue in the downstream T-domain ([@B112]; [@B214]; [@B141]).

### Condensation Domains (C)

C-domains are approximately 450 residue NRPS domains, representing a highly versatile class of NRPS domains. Any NRPS composed of more than one module must consequently contain at least one C-domain. However, also single modular NRPS may contain C-domains, especially if they cooperate with other NRPS. Essentially, the primary target of a C-domain is the condensation of the up- and downstream activated substrates through a nucleophilic attack, mainly leading to the formation of an n-peptide linked via a peptide bond. Nonetheless, several residues of the C-domain may have the intrinsic potential to fulfill multiple functions ([@B10]; [@B196]; [@B85]).

### Epimerization Domains (E)

The E-domains are among the most abundant modification domains intrinsic to NRPS. In contrast to the structurally similar C domains they are responsible for the site specific epimerization of a substrate, predominantly performing this function after peptide bond formation has occurred ([@B22]).

### Thioesterase Domains (Te)

The thiotemplate based enzymatic systems rely on a catalytic activity in order to remove a product or product-scaffold of the primary enzyme. Therefore, most NRPS contain a domain on their C-terminus responsible for precisely this purpose, the thioesterase domain (Te). Te-domains are a common commodity in single and multi-modular NRPS, although, in multi-NRPS systems only the terminal NRPS contains this domain ([@B90]). Additionally, this domain harbors a quality control activity (proofreading) to verify the correct configuration of the nascent peptide ([@B127]).

### Intrinsic Product Modifying Domains

In addition to the C-domain related epimerization domain, discussed previously, there are cyclization (Cy), oxygenation (Oxy) as well as methyl-transferase (MT). These domains have been characterized to the extent of classifying their functions, although, especially Cy- and Oxy-domains may occur as a singular bi-functional unit or in a serial manner, respectively ([@B203]). Cy- and Oxy-domains, specifically replace the classic function of C-domains, omitting amino acid condensation through peptide bond formation, resulting in thiazoline, oxazoline or methyloxazoline structures ([@B193]; [@B203]). Those reactions predominantly occur in siderophore producing NRPS and rely on the presence of serine, threonine and cysteine residues ([@B153]; [@B105]). Also MT-domains follow the common di-sub-domain structural patterning, which is also seen in A-, C-, E-, and Cy-domains. Fundamentally, MT-domains, however, are more restricted in their function, which covers the transfer of methyl-groups from *S*-adenosylmethionine to N (N-MT), C (C-MT), O (O-MT) or for certain residues S (S-MT) atoms resolving around the amino acids C~α~ carbon ([@B137]) and in case of S-MT C~β~, respectively ([@B4]).

In *P. chrysogenum* 10 NRPS have been identified (Table [1](#T1){ref-type="table"}) ([@B200]; [@B131]; [@B172]), of which only two have no attributed function. In this fungus, next to fungisporin (Figure [1](#F1){ref-type="fig"}) which is a cyclic hydrophobic tetrapeptide generated by a singular NRPS, three biosynthetic pathways involving a NRPS have been described in detail: penicillins, roquefortine/meleagrin, fungisporin and chrysogine (Figure [4](#F4){ref-type="fig"}).

###### 

Nonribosomal peptide synthetases (NRPSs) in *P. chrysogenum* and known associated products.

  Gene ID        Gene name   Protein                                              Domain organization                     Product/Pathway
  -------------- ----------- ---------------------------------------------------- --------------------------------------- ------------------------
  *Pc13g05250*   *pssC*      Siderophore synthetase                               A~1~TCA~2~TCTCA~3~TCTCT                 Siderophore
  *Pc13g14330*   *--*        Tetrapeptide synthetase                              CA~1~TECA~2~TCA~3~TCA~3~TCA~4~TC        --
  *Pc16g03850*   *pssA^∗^*   Siderophore synthetase                               ATCTA                                   Coprogen
  *Pc16g04690*   *hcpA*      Cyclic tetrapeptide synthetase                       A~1~TECA~2~A~3~TCA~4~TECTCT             Fungisporin
  *Pc21g01710*   *nrpsA*     Dipeptide synthetase                                 A~1~TCA~2~T                             Brevianamide F
  *Pc21g10790*   *--*        Hexapeptide synthetase                               A~1~TCA~2~TCA~3~TECA~4~TCA~5~TCA~6~TC   --
  *Pc21g12630*   *chyA*      2-Aminobenzamide synthetase                          A~1~TCA~2~TC                            Chrysogine
  *Pc21g15480*   *roqA*      Histidyl-tryptophanyldiketo- piperazine synthetase   A~1~TCA~2~TC                            Roquefortine/Meleagrin
  *Pc21g21390*   *pcbAB*     α-Aminoadipyl-cysteinyl-valine synthetase            A~1~TCA~2~TCA~3~TEte                    β-lactams
  *Pc22g20400*   *pssB*      Siderophore synthetase                               ATCTC                                   Fusarinines
                                                                                                                          

A, adenylation; T, thiolation; E, epimerization; te, thioesterase; C, condensation.

∗

Point mutations present in

nrps

genes of industrial

P. chrysogenum

strains subject to CSI program. Modified from

Salo et al. (2015)

,

Samol et al. (2016)

, and

Guzmán-Chávez et al. (2018)

.
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Polyketides and Polyketide Synthase
-----------------------------------

Polyketides were already discovered in 1883 by James Collie, but the interest in these compounds (enzymes) was revived only as late as the 1950s by the work of Arthur Birch on the aromatic polyketide-6-methyl salicylic acid from *P. patulum*. These molecules are a class of NPs, that display different types of biological activities such as antibiotic (erythromycin A), antifungal (amphotericin B), immunosuppressant (rapamycin), antitumor (geldanmycin) and hypolipidemic (lovastatin) ([@B139]; [@B98]; [@B215]). Their assembly process is similar to that in the fatty acid biosynthesis, the main difference is the optional full reduction of the β-carbon in the PK biosynthesis. The group of enzymes that catalyzes the biosynthesis of PKs is referred to as PKSs ([@B104]; [@B35]).

In addition to the NRPSs, PKSs are the main enzymes that build the structural scaffold of a wide range of secondary metabolites and NPs in plants, bacteria, insects and fungi ([@B27]; [@B139]). Usually, these enzymes are encoded by genes that are grouped into clusters, that also specify genes encoding tailoring enzymes (oxygenases, oxidoreductases, reductases, dehydrogenases, and transferases), that further modify the scaffold produced by the PKS into a final product ([@B27]; [@B117]). PKSs are multimodular and multidomain enzymes that use a specific acyl-coenzyme A (acyl-CoA; usually malonyl-CoA or methylmalonyl-CoA) as building block, and subsequently catalyze a decarboxylative Claisen-type condensation of ketide units. The basic structural architecture consists of an acyl carrier protein (ACP), a ketosynthase (KS) and an acyltransferase (AT) domain. These combined domains extent a linear intermediate by two carbon atoms. An optional set of domains (dehydratase (DH), ketoreductase (KR), enoyl reductase (ER) and thioesterase (TE) may provide further modifications of the linear intermediate ([@B189]; [@B27]; [@B139]; [@B64]).

According to their protein architecture and mode of action, PKS enzymes are classified into types I, II, and III (Figure [5](#F5){ref-type="fig"}). ***Type I PKSs*** are mainly found in bacteria and fungi. These multidomain proteins can be further subdivided in two categories: *modular* and *iterative* ([@B139]) *Modular type I PKSs* or *non-iterative PKSs* are unique for bacteria and are characterized by presenting a sequence (or set) of modules, each constituted with a set of specific catalytic domains. In consequence, the number of precursors fused in the PK is equivalent to the number of modules which are present ([@B40]). In contrast, *iterative type I PKSs* use the same catalytic core domains as modular type I PKSs, but the catalytic reaction is repeated to yield the complete PK backbone. A representative example of this type is LovB, that together with LovC (a enoyl reductase) catalyzes around 35 reactions to produce dihydromonacolin L, an intermediate in the lovastatin biosynthesis ([@B40]; [@B36]). Like iterative type I PKS enzymes, fungal PKSs (Figure [2B](#F2){ref-type="fig"}) are restricted to a single module and the consecutive domains act in sequential order during the synthesis of the complete PK. They are equipped with basic structural domains typically found in PKS enzymes (ACP-KS-AT domains) but may also contain optional units (KR, DH, ER, and Te domains). Depending on the presence or absence of reducing domains, these enzymes can be divided into *highly reducing (HR)*, *non-reducing (NR)* and *partially reducing (PR)* PKS (Figure [2B](#F2){ref-type="fig"}) ([@B104]; [@B51]; [@B98]).

![Mode of biosynthesis of polyketide synthases. For details see the text. Abbreviations are as in the legend to Figure [2](#F2){ref-type="fig"}. Iterative type I PKS is depicted in Figure [2B](#F2){ref-type="fig"}.](fmicb-09-02768-g005){#F5}

### Highly Reducing PKS (HR-PKS)

*Highly reducing PKS (HR-PKS)* produce the linear or cyclic scaffold of some compounds such as fumonisins, T-toxins, solanapyrone E, squalestatin or/and lovastatin ([@B45]; [@B165]). Usually, they start with a KS domain, followed by an AT, DH and C-Met domain, although the latter does not always follow the DH domain. The ER domain is an optional unit in HR-PKS enzymes, but when the ER is missing, the corresponding region is filled with a polypeptide domain with an unknown function. Furthermore, these enzymes do not contain a product template domain (PT) or N-terminal SAT domain, whereas these special domains are present in NR-PKS enzymes ([@B50]).

### Partially Reducing PKS (PR-PKS)

Structurally, these enzymes have a domain architecture that is similar to the mammalian FAS: a N-terminal KS-domain followed by an AT-, DH-, and "*core*"-KR-ACP domain. These enzymes lack an ER domain ([@B206]), and also do not have a Te domain, which suggests an alternative mechanism of product release than hydrolysis. PR-PKS enzymes produce small aromatic molecules such as 6-methylsalicylic acid (MSA), but in most cases the chemical product is unknown ([@B49], [@B50]; [@B99]).

### Non-reducing PKS (NR-PKS; Aromatic PKs)

*Non-reducing PKS* (NR-PKS; aromatic PKs) typically, consist of six catalytic domains that are covalently associated and arranged in four components: *loading (SAT), chain extension (KS-MAT-PT-ACP), cyclisation and processing components (TE-CLC)* ([@B32]).

***Type II PKSs*** are unique for bacteria and use a similar iterative mechanism as observed in *iterative type I PKSs*. However, the different catalytic domains are encoded by independent genes. In general, they often constitute a "minimal PKS," which comprises of two KS units (KS~α~ and KS~β~) and an ACP protein that holds the growing PKS chain. The KS~β~ domain defines the length of the PK chain. The folding pattern of the poly-β-keto intermediates is determined by optional PKS units such as aromatases, ketoreductases, and cyclases. Other tailoring modifications are performed by oxygenases, methyl and glycosyl transferases. Known metabolites synthetized by type II PKSs are tetracyclines, anthracyclines and aureolic acids ([@B87]; [@B98]).***Type III PKSs*** have originally been discovered in plants but are also present in bacteria and fungi. They consist of a single KS domain that catalyzes a defined number of elongations, usually generating small phenols or naphtol rings. The enzyme transfers the acyl group from the CoA to the active site histidine, which is a highly conserved residue. However, the amino acid sequence of the his motif is not similar to those found in KS domains of type I and II PKS enzymes ([@B179]; [@B40]; [@B31]; [@B98]). Importantly, independent of the mechanistic or structural differences, all the PKs synthetized by PKS enzymes follow the same decarboxylative condensation mechanism of the acyl-CoA precursors. However, these precursors should be activated in prior by the ACP domain, in the case of the type I and II PKS enzymes, whereas type III PKS enzymes act independently of ACP domains ([@B179]; [@B89]). Acridones, pyrenes as well as (and) chalcones are some examples of the compounds produced by type III PKS enzymes ([@B225]). Below, a brief description is provided on the main catalytic features of PKS domains.

### Acyltransferase Domains (AT)

A main unit during PK biosynthesis is the AT domain that selects the starter unit (malonyl-CoA or methylmalonyl-CoA) before it is transferred to the ACP domain for the chain elongation cycle ([@B63]). This process involves two steps, i.e., the acylation and the transfer to the ACP ([@B98]).

### Acyl Carrier Protein (ACP)

The ACP is an essential cofactor that participates in PK biosynthesis. This protein belongs to a highly conserved carrier family, and consists of 70--100 amino acid residues ([@B33]). To perform the PK biosynthesis, the *holo-ACP* (active) form is generated by the phosphopantetheinyl transferase enzyme (PPTase) through a post-translational modification of ACP whereby a 4′-phosphopantetheine (4′-PP) moiety from CoA is transferred to the conserved serine ([@B66]; [@B100]; [@B98]) resulting in the formation of the Ppant arm. ACP modulates three important events during PK biosynthesis. First, it allows the condensation during chain elongations since it transfers the starter unit from the AT domain to the KS domain. Second, it shuttles the growing chain between the up and downstream domains, as well as to optional PKS domains, probably involving protein--protein recognition between domains. Third, it prevents premature cyclization and enolization of the PK chain ([@B220]).

### Ketosynthase Domains (KS)

The KS is a homodimeric condensing domain that catalyzes the extension of the β-ketoacyl intermediate by a decarboxylative Claisen condensation. This domain contains two active sites which are accessible to the ACP through its flexible Ppant arm, which receives the β-carboxyacyl-CoA extender unit from the AT. At that stage, a thioester bond is formed between the active-site cysteines' thiol group of the KS and the growing PK. Only when both units are covalently attached onto the module, a decarboxylative Claisen condensation occurs, which involves two conserved his residues. Therefore, mechanistically the KS domain acts at three stages: acylation, decarboxylation and condensation ([@B42]; [@B35]; [@B220]; [@B98]; [@B164]).

### Ketoreductase Domains (KR)

The KR domain functions as a β-carbon processing unit that belongs to the family of short-chain dehydrogenase/reductases. This domain reduces the β-keto group, that is formed during the condensation process, into a hydroxyl group (a β-hydroxyl intermediate) using NADPH ([@B102]; [@B35]). Additionally, some KR domains are equipped with epimerase activity. The epimerizing module has a more open architecture, enabling the catalytic epimerization of methyl groups in acyl-ACP substrates, a reaction that involves the conserved serine and tyrosine residues which are also employed during ketoreduction ([@B150]c; [@B15]).

### Dehydratase Domains (DH)

The DH domain is usually coupled to B-type KR domains (B-type). This domain catalyzes water elimination (via *syn* or *anti*) at the β-hydroxy acyl chain position thereby producing *trans* double bonds (α,β-unsaturated moieties) ([@B35]; [@B31]; [@B98]; [@B15]).

### Enoyl Reductase Domains (ER)

The ER domain is an optional tailoring unit involved in the final oxidation state of the growing PK. It reduces α,β-enoyl groups and thereby generates saturated α--β bonds. This reaction involves NAD(P)H as hydride donor in a Michael addition type of mechanism. In the enoyl reduction, the products formed during this reaction have a specific stereochemistry (3R,2R) or (3R,2S) due to the β-carbon attack performed by the pro-4R hydride of NADPH, contrasting the KR domain that utilizes the pro-4S hydride ([@B42]; [@B31]).

### Thioesterase Domain (Te)

Termination of PK biosynthesis involves the Te domain, which produces macrolactones via intramolecular cyclization or linear PKs by hydrolysis ([@B101]). In both events, an acyl-Te intermediate is formed through the transfer of the PK chain from the last ACP to the active serine on Te domain ([@B98]).

### Special Domains

In *non-reducing PKS*, the **ACP transacylase (SAT)** domain acts as starter unit that loads the ACP whereupon chain extension is mediated for KS and AT domain. During this process, the malonyl-CoA:ACP transacylase **(MAT) domain** transfers the extension units from malonyl-CoA to the ACP, while the product template **(PT) domain** stabilizes the reactive poly-β-keto intermediates. The processing component acts after the initial assembly when the cyclized or PK intermediate is still attached to the ACP. Final cyclization and release is catalyzed by the Te/Claisen cyclase **(CLC) domain** ([@B50]; [@B51]; [@B32]; [@B45]).

In *P. chrysogenum*, 20 PKS genes have been identified (Table [2](#T2){ref-type="table"}) ([@B200]; [@B131]; [@B172]), but for only six the products are known. To date, in *P. chrysogenum* only four PK-related pathways have been described in detail: sorbicillinoids, MSA-6/yanuthones, DHN-melanin and andrastin A (Figure [6](#F6){ref-type="fig"}).

###### 

Polyketide synthases in *P. chrysogenum* and (insofar known) their associated products.

  Gene ID        Gene name    Protein                Domain organization     Product/Pathway
  -------------- ------------ ---------------------- ----------------------- ------------------
  *Pc12g05590*   *pks1*       --                     ks-at-dh-mt-kr-acp      --
  *Pc13g04470*   *pks2^∗^*    --                     ks-at-dh-mt-er-kr-acp   --
  *Pc13g08690*   *pks3*       --                     ks-at-dh-mt-er-kr-acp   --
  *Pc16g00370*   *yanA*       6-MSA synthase         ks-at-kr-acp            6-MSA/Yanuthones
  *Pc16g03800*   *pks5*       --                     ks-at-dh-er-kr-acp      --
  *Pc16g04890*   *pks6*       --                     ks-at-dh-mt-er-kr-acp   --
  *Pc16g11480*   *pks7^∗^*    --                     ks-at-dh-mt-er-kr-acp   --
  *Pc21g00960*   *pks8^∗^*    --                     ks-at-dh-mt-er-kr-acp   --
  *Pc21g03930*   *pks9*       --                     ks-at-dh-mt-er-kr-acp   --
  *Pc21g03990*   *pks10*      --                     ks-at-dh-er-kr-acp      --
  *Pc21g04840*   *pks11*      --                     ks-at-dh-er-kr-acp      --
  *Pc21g05070*   *sorB^∗^*    Sorbicillin synthase   ks-at-acp-mt-te/red     Sorbicillinoids
  *Pc21g05080*   *sorA^∗^*    Sorbicillin synthase   ks-at-dh-mt-er-kr-acp   Sorbicillinoids
  *Pc21g12440*   *pks14*      --                     ks-at-dh-er-kr-acp      --
  *Pc21g12450*   *pks15^∗^*   --                     ks-at-acp-te            --
  *Pc21g15160*   *pks16*      --                     ks-at-dh-mt-er-kr-acp   --
  *Pc21g16000*   *alb1^∗^*    YWA1 synthase          ks-at-acp-acp-te        YWA1/DHN-Melanin
  *Pc22g08170*   *patK*       6-MSA synthase         ks-at-kr-acp            6-MSA
  *Pc22g22850*   *adrD*       DMOA synthase          ks-at-acp-mt-te/red     DMOA/Andrastin A
  *Pc22g23750*   *pks20*      --                     ks-at-dh-mt-er-kr-acp   --
                                                                             

ks, ketosynthase; at, acyltransferase; dh, dehydratase; mt, methyltransferase; er, enoyl reductase; kr, ketoreductase; acp, acyl carrier protein; te/red, thioester reductase.

∗

Point mutations present in

pks

genes of industrial

P. chrysogenum

strains subject to CSI program. Modified from

Salo et al. (2015)

,

Samol et al. (2016)

, and

Guzmán-Chávez et al. (2018)

.

![PKS-based biosynthetic pathways in *P. chrysogenum. Sorbicillinoids:* Despite the fact that this cluster is also present in industrial strains of *P. chrysogenum*, they do not produce sorbicillinoids due to a point mutation in the ketosynthase domain of SorA. *Yanuthones/Patulin: P. chrysogenum* only contains a full version of one cluster (yanuthone D BGC), while the second cluster (patulin BGC) is incomplete ([@B143]). The absence of the gene encoding for an isoepoxidon dehydrogenase agrees with the fact that this fungi does not produce patulin ([@B172]). However, under laboratory conditions, yanuthone D is also not detected in this fungus ([@B170]). *DHN-Melanin:* The genes are only partially clustered in the genome of *P. chrysogenum*. *Andrastin A: P. chrysogenum* strains subjected to CSI are not able to produce andrastin A or related compound. Adapted from [@B189], [@B128], [@B48], [@B209], [@B62], [@B154], [@B51], [@B8], [@B83], [@B75], [@B86], [@B129], [@B169], [@B171], [@B60], [@B133], [@B170], [@B172], [@B80], [@B81], [@B143], and [@B167].](fmicb-09-02768-g006){#F6}

Terpenoids Biosynthesis
-----------------------

In addition to NRPs and PKs, terpenoids are another class of NPs that are synthetized by filamentous fungi (Ascomycota) although less abundant as compared to Basidiomycota ([@B176]). Fungal terpenoids or isoprenoids are structurally diverse molecules derived from isoprene units (C5 carbon skeleton): isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), which are synthetized in the mevalonate pathway from acetyl-CoA ([@B45]; [@B185]). The head-to-tail condensation of these C5 units is catalyzed by isoprenyl diphosphate synthases (IDSs), producing isoprenyl diphosphates with 10 (geranyl, GPP), 15 (farnesyl, FPP), and 20 (geranylgeranyl, GGPP) carbons. Eventually, these linear chains of different length are further modified by cyclases, terpene synthases (TPs) and prenyl transferases (PTs), yielding different subclasses of terpenoids ([@B176]; [@B43]). For instance, monoterpenoids, sesquiterpenoids, diterpenoids, sesterterpenoids, and triterpenoids, which harbor two to six isoprene units, respectively ([@B185]). Terpenoids are oxygenated derivatives of terpenes, which are also derived of isoprene ([@B188]).

In filamentous fungi such as *Aspergillus*, *Penicillium*, *Claviceps*, and *Neosartorya*, ABBA-type PTs are involved in the biosynthesis of a range of toxins ([@B176]). For the synthesis of indole-diterpenoids, IPPS-type PTs transfer GGPP to a indole group, while UbiA-type PTs are involved in the biosynthesis of meroterpenoids, which are hybrid NPs (terpenoids and PKs) ([@B93]; [@B176]). In *A. nidulans*, AusN (UbiA-type TPs) converts the product of a NR-PKS (3,5-dimethylorsellinic acid) as part of an earlier step in the dehydroaustinol/austinol biosynthesis pathway ([@B120]).

Terpene synthases catalyze cyclization reactions forming the carbocation by substrate ionization (class I) or substrate protonation (class II) ([@B228]; [@B132]). A relevant example of class I TPs are sesquiterpene synthases, which cyclize the FPP to obtain a sesquiterpene scaffold (C15 backbone) ([@B159]). Recently, the *prx1* to *prx4* gene cluster involved in the biosynthesis of PR-toxin in *P. roqueforti* was cloned and sequenced. This cluster contains the gene *prx2* (*ari1*) that encodes for a aristolochene synthase which forms a sesquiterpene aristolochene derivative (precursor of PR-toxin). Interestingly, an orthologous gene cluster was identified in *P. chrysogenum* (Pc12g06300 to Pc12g06330), as part of BGC of eleven genes, which is also involved in the biosynthesis of PR-toxin ([@B88]).

Strategies for Activation of BGC[s]{.smallcaps}
===============================================

Natural products represent a broad range of molecules produced by animals, plants and microorganisms. These molecules may display different biological activities (e.g., antiviral, antimicrobial, anti-tumor, immunosuppressive agents) and it is estimated that the majority of these compounds are derived from filamentous fungal sources and from filamentous bacteria belonging to the genus *Streptomyces*. With respect to antibiotics, most of the chemical scaffolds used today were discovered during the golden age of antibiotics discovery (1940--1960s). This was followed by four decades during which hardly any new scaffolds from a natural source were developed ([@B160]; [@B183]; [@B149]). However, there is also a current understanding that only a small fraction of the potential possible molecules has been discovered to this date. This follows from genomic studies revealing large numbers of uncharacterized BGCs, while many of these gene clusters are not expressed (silent or sleeping gene clusters) under laboratory conditions ([@B28]). Furthermore, metagenomics studies indicate that the majority of microbes present in the environment have not been cultured nor characterized. Thus, there are many challenges that need to be overcome in order to harness the natural diversity of NPs, to cultivate potential strains under laboratory conditions and to activate the BGCs for expression. To achieve the synthesis of new NPs, three main approaches (Figure [7](#F7){ref-type="fig"}) were used in recent years, which may be successfully applied in *P. chrysogenum*: manipulation of cultivation conditions, engineering of NRPS and PKS and genetic interference.

![Regulatory targets and strategies to engineer *P. chrysogenum* and other filamentous fungi for secondary metabolite formation. For details see the text.](fmicb-09-02768-g007){#F7}

Manipulation of Cultivation Conditions
--------------------------------------

Under natural conditions, fungi face a variety of biotic and abiotic conditions to survive. The cellular response to the environment involves complex regulatory networks that respond to stimuli such as light, pH, availability of carbon and nitrogen sources, reactive oxygen species, thermal stress, and interspecies-crosstalk ([@B27]; [@B160]).

### OSMAC (One Strain Many Compounds) Approach

This strategy is derived from the observation that changes in the metabolic output of microorganisms can be achieved by alternating the medium composition and other cultivation parameters. It is well known that glucose, ammonium, or phosphate at high concentrations act as repressors of secondary metabolism, whereas iron starvation and nitrogen limitation can stimulate secondary metabolite production. The latter is for instance exploited for the production of terrain by *A. terreus* ([@B23]; [@B28]; [@B79]). This strategy can readily be implemented using high-throughput methods, where an array of culture conditions can be screened for new metabolite profiles ([@B186]). In combination with bioinformatics tools, this strategy can be a powerful tool to investigate the production of new molecules, as exemplified by the discovery of aspoquinolones A--D in *A. nidulans* ([@B175]). However, despite the fact that the OSMAC approach has led to the discovery of increased numbers of new molecules with antimicrobial activity, some chemical and physical conditions are still missing under the laboratory tested conditions as the activation often concerns a limited number of BGCs ([@B44]).

### Interspecies-Crosstalk

The production of secondary metabolites is a natural strategy that microorganisms have developed to cope with specific environmental conditions and challenges. They serve as intermediary agents to establish a symbiotic association between species or as a weapon against other organism to compete for nutrients and space. These conditions, that are not present in axenic cultures, boost the production of molecules that are constitutively present and/or that are cryptic and normally are not synthetized due to silencing of the respective BGCs ([@B54]; [@B126]). The strategy in which different organisms are cultivated together is called "*co-culture*," which has been successful in several cases yielding new metabolites. *A. fumigatus* produces fumiformamide when co-cultivated with *Streptomyces peucetius*, while co-cultivation of this fungi with *S. rapamycinicus* results in the production of fumicyclines A and B, two novel PKs with antibacterial activity, are examples of the use of this strategy ([@B140]; [@B2]). Interestingly, the association of two marine organisms, *Emericella* sp. and *Salinispora arenicola*, results in the biosynthesis of emericellamides A and B which are equipped with antibacterial activity ([@B148]). Also, the interactions between fungi and insects result in the production of volatile secondary metabolites ([@B166]).

Engineering of NRPS and PKS
---------------------------

Nonribosomal peptide synthetase and PKS are highly structured and multi-facetted enzymes, containing a tremendous potential for the exploitation of their product scaffold structure for the generation of novel, bioactive compounds. However, due to the complexity of all interactions within these mega enzymes, the elucidation and implementation of engineering strategies is an extremely challenging task. Several strategies have been developed and applied with different degrees of success, though the overall approaches can be grouped as module, domain, sub-domain or site directed, respectively. Owing to their large size, utilization of a random mutagenesis approach proved to be difficult, but other more directed strategies are met with a great success. Nevertheless, all of these strategies have their inherent difficulties, advantages and disadvantages in respect to the complexity and success rate of NRPS/PKS engineering efforts.

### Subunit, Module, and Domain Swapping

Extensive efforts targeting the active site of A-domains has been a major focus in NRPS engineering. Multiple studies confirmed that the substrate specificity of a NRPS A-domain can be successfully altered, however, at the cost of substantially lowered catalytic velocity ([@B197]; [@B227]). Similar successes and limitations were observed when domains were swapped or replaced by synthetic versions ([@B17]). The most challenging way of obtaining novel NRPS, however, is the swapping or combining of entire modules ([@B111]). Domain swapping overall created not only functional parts or domains, but also complete NRPS though with limited success ([@B17]).

Due to the strict arrangement of NRPS in domains and modules, the possibility of exchanging a unit appears to be the most straight forward approach for altering its intrinsic properties. A series of studies targeting the enzymes linked to the production of daptomycin ([@B142]; [@B12]) elucidated the possibilities and borders of a combinatorial swapping strategy in context of novel compound production. The daptomycin biosynthetic cluster comprises three NRPS containing a total of 13 modules for the incorporation of an equal number of substrates. Different levels of domain and module swap approaches were followed, starting with the exchange of modules 8 and 11 (C-A-T), representing an internal module exchange. The resulting NRPS exhibited the production of novel daptomycin compounds with an inverted amino acid composition at the predicted sites at a near native rate ([@B142]). A similar combinatorial approach has been chosen for altering the PK stereochemistry. The exchange of a R domain with a TE domain in a NR-PKS from *A. niger* produced two alternative NR-PKS that harbor carboxylic acids instead of the aldehydes present in the original products ([@B221]; [@B215]). In *Aspergillus*, this rational domain swap has also been used to diversify the native substrates that NR-PKS takes as starter unit to produce new products. This involved exchanging the starter unit ACP transacylase domain in the PKS ([@B119]). Likewise, an analogous approach was used to produce new hybrids (PK--NRPs) in *A. nidulans* via module swapping of the two PKS--NRPS natural hybrids involved in the syn2 and cytochalasin E pathways from *Magnaporthe oryzae* and *A. clavatus* respectively ([@B144]). Despite the successful use of this strategy in some filamentous fungi, the engineering of NRPS and PKS in *P. chrysogenum* remains unexplored.

Genetic Interference
--------------------

Another mechanism to stimulate the expression of silent BGCs in *P. chrysogenum* is by genetic interference, for instance by direct manipulation of the regulatory network related to BGCs expression. The regulation of BGCs is effected at many levels, through specific (or local) and global regulators up to epigenetic regulation involving the modification of the chromatin landscape ([@B117]; [@B186]).

### Global and Specific Regulators

#### Global regulator-based regulation

Pleiotropic transcriptional regulators or global regulators are proteins that respond to environmental signals such as pH, temperature, and N- and C-sources. They provide the link between the production of secondary metabolites and external cues. In fungi, these proteins control the regulation of BGCs that do not contain other regulatory factors. Up to 40% of the known clusters do not encode a local and specific regulator (or obvious regulatory genes). Additionally, global regulators also act on genes that do not belong to secondary metabolism ([@B27]; [@B168]; [@B71]). Global regulators that have been reported as key players in the biosynthesis of secondary metabolites are featured below.

##### Velvet complex

This heterotrimeric complex is a conserved regulator present in most of the fungi, except yeast. It consists of at least three proteins: VeA, VelB, and LaeA. Likewise, this complex provides a link between sexual development and secondary metabolism through light regulation ([@B222]; [@B53]), since light has an inhibitory effect on VeA expression. The formation of the velvet complex takes place in the nucleus, where the complex VeA--VelB via the α-importin KapA meets the methyltransferase LaeA. It has been hypothesized that the velvet complex acts as a transcriptional factor as it contains a DNA binding fold that resembles the corresponding region of the NF-κB transcription factor of mammals ([@B173]). The role of the velvet complex in secondary metabolism mostly follows from the control that the LaeA protein executes on several BGCs in filamentous fungi. LaeA ([l]{.ul}oss of [a]{.ul}flR [e]{.ul}xpression-[A]{.ul}) was identified in 2004 as a global regulator in *Aspergillus*. Deletion of this gene results in the repression of many BGC, such as the one responsible for the production of penicillin, lovastatin, and sterigmatocystin. Overexpression of LaeA causes an opposite phenotype. Interestingly, LaeA is negatively regulated by AflR (Zn~2~Cy~6~ transcriptional factor) in a feed loop mechanism ([@B25]). It has been hypothesized that LaeA acts at different levels, i.e., as a methyltransferase, epigenetically and as a direct member of the velvex complex. Structurally, LaeA has a *S*-adenosyl methionine (SAM)-binding site with a novel *S*-methylmethionine auto-methylation activity, although this activity does not seem to be essential for its function. LaeA is not a DNA-binding protein, but it does affect chromatin modifications. In an *A. nidulans ΔlaeA* strain, high levels of the heterochromatin protein 1 (HepA) are detected and an increase in trimethylation of the H3K9 in the sterigmatocystin cluster. When LaeA is present, the levels of HepA, ClrD (H3K9 methyltransferase) and H3K9me3 decrease while the sterigmatocystin levels are raised. The heterochromatic marks stay until the sterigmatocystin cluster is activated, and apparently LaeA influences the offset of these marks in this particular cluster ([@B161]; [@B27]; [@B94]; [@B173]; [@B26]). Orthologs of LaeA have been discovered in many other filamentous fungi as *Penicillium*, *Fusarium*, *Trichoderma*, *Monascus* spp. and LaeA exhibits positive and negative effects on the synthesis of NPs. For instance, LaeA1 of *F. fujikuroi* positively regulates the production of fusarin C, fumonisins and gibberellins, and represses bikaverin biosynthesis. In *P. chrysogenum*, LaeA controls the biosynthesis of penicillin, pigmentation and sporulation ([@B104]; [@B110]; [@B94]). In *Trichoderma reesei*, Lae1 positively modulates the expression of cellulases, xylanases, β-glucosidases. Interestingly the stimulation of these genes was not directly influenced by the methylation of H3K4 or H3K9 ([@B216]; [@B222]; [@B117]; [@B178]; [@B94]).

LaeA is not the only member of the velvet complex that has influence on the regulation of secondary metabolite production. *VeA* of *A. parasiticus* is necessary for the expression of two transcriptional factors of the aflatoxin cluster (AflR and AflJ), which regulate the pathway. In *A. fumigatus*, veA regulates 12e BGCs ([@B58]). This study also revealed that veA modulates the biosynthesis of fumagillin via the regulation of FumR, a transcriptional factor of the fumagillin cluster, which in turn is also regulated by LaeA. Similarly, a transcriptome analysis in *A. flavus* revealed that 28 of 56 BGCs are dependent on *veA*, in particular the aflavarin cluster which is differentially expressed. Likewise, orthologs of veA are also present in other fungi such as in *P. chrysogenum*, *F. oxysporum, Botrytis cinerea*, *F. verticillioides* ([@B222]; [@B58]; [@B94]; [@B37]). Despite the clear interaction between veA and LaeA in the velvet complex and its influence on secondary metabolism, it is thought that veA may be acting as molecular scaffold of the velvet complex, since it interacts also with three other methyl transferases \[LaeA-like methyltransferase F (LlmF), velvet interacting protein C (VipC), and VipC associated protein B (VapB)\]. This suggests that veA functions in a supercomplex or in dynamic network control. Taken together, modulation of the velvet complex is a useful tool to activate BGCs ([@B173]) but results are difficult to predict.

##### bZIP transcription factors

Basic leucine zipper (bZIP) transcription factors are highly conserved in the eukaryotes. The dimeric bZIP transcriptional factors play an important role in the cellular responses to the environment. Regarding their structure, they contain a conserved leucine zipper domain and a basic region, which controls the dimerization of the protein and establishes sequence-specific DNA-binding, respectively. Once dimeric, bZIPs target palindromic DNA sequences by two mechanisms: redox and phosphorylation ([@B6]; [@B109]). In fungi, bZIP proteins have been implicated in multiple metabolic processes, such as in the regulation of development, morphology and in stress responses. Several orthologs of the Yap family bZIPs, which were first described in yeast, have been characterized in *Aspergillus* spp. (AtfA, NapA, Afyap1, Aoyap1, and Apyap1) and these regulators have recently been associated with the production of secondary metabolites in filamentous fungi. In *A. nidulans*, overexpression of *RsmA* (restorer of the secondary metabolism A, Yap-like bZIP) has a compensatory effect on secondary metabolism in a strain in which LaeA and veA are missing. However, these transcription factors also display negative regulation. For instance, an increase in the biosynthesis of aflatoxin and chratoxin has been observed when *yap1* is deleted in *A. parasiticus* and *A. ochraceus* ([@B223]; [@B109]; [@B207]). MeaB is another bZIP transcriptional factor which was discovered in *A. nidulans*. Its function is associated in nitrogen regulation and has a negative effect on the biosynthesis of aflatoxin in *A. flavus* and bikaverin production in *F. fujikuroi* ([@B202]; [@B5]).

##### Other global regulators

AreA is a highly conserved transcriptional factor in fungi that belongs to the GATA family and it is characterized by Cys~2~His~2~ zinc finger DNA binding domains. Likewise, it is involved in the repression of nitrogen metabolism when ammonium or glutamine are present. Recently, this transcription factor and its orthologs have been shown to influence secondary metabolism. For instance, *areA* deletion strains of *F. verticillioides* are not able to produce fumonisins on mature maize kernels. In *Acremonium chrysogenum*, the deletion of *areA* resulted in the reduction of cephalosporin because of a reduced expression of the enzymes involved in cephalosporin biosynthesis. Additionally, AreA is a positive regulator of the production of gibberellins, trichothecene deoxynivalenol (DON), fusarielin H, beauvericin and zearalenone ([@B115]; [@B198]; [@B109] and [@B103]). The carbon catalytic repressor CreA also influences secondary metabolism. CreA is a Cys~2~His~2~ zinc finger transcription factor that is involved in the repression of genes associated with the use of carbon sources other than glucose (Knox and [@B103]). This transcription factor acts by direct competition with activator proteins for specific binding sites (5′-SYGGRG-3′) and by direct interaction with activators ([@B97]). In *P. chrysogenum* CreA represses penicillin biosynthesis and causes a reduced expression of the *pcbAB* gene that encodes a NRPS involved in this pathway. Mutations in the putative CreA binding site in the *pcbAB* promoter result in enhanced enzyme expression when cells are grown in the presence of glucose ([@B38]). In contrast, mutations in the CreA binding sites of the *ipnA* promoter (*pcbC* in other species) of *A. nidulans* revealed that in this organism repression of penicillin biosynthesis by glucose is independent of CreA (Knox and [@B103]). CreA has been implicated in the variable metabolite profiles when fungi are grown in the presence of different carbon sources ([@B226]). Recently, the xylanase promoter binding protein (Xpp1) of *Trichoderma reesei* was used as a reporter to fulfill a dual role in the regulation of primary and secondary metabolism. Xpp1 is an activator of primary metabolism, while its deletion boosts the production of secondary metabolites, including sorbicillinoids ([@B56]). Another Cys~2~His~2~ zinc finger transcription factor conserved in fungi is PacC, which is involved in pH dependent regulation. Deletion of the ortholog of this gene (BbpacC) in *Beauveria bassiana* resulted in a loss of dipicolinic acid (insecticide compound) and oxalic acid production, compounds that reduce the pH of the medium. However, also production of a yellow pigment was noted. When *A. nidulans* is grown at alkaline pH, PacC modulates the expression of the *acvA (pcbAB)* and *ipnA* of the penicillin BGC, while it acts negatively on the expression of the sterigmatocystin BGC ([@B53]; [@B121]). In filamentous fungi, another global regulatory element is the CCAAT-binding complex (CBC). This complex consists of three proteins (HapB, HapC, and HapE) that respond to redox stimuli and an additional unit HapX, a bZIP protein that interacts with the complex for modulating the iron levels. In *A. nidulans* this complex binds to CAATT motifs, which are present in the penicillin BGC stimulating the expression of the *ipnA* and *aatA* (*penDE*) genes ([@B16]; [@B27]). Whereas in *F. verticillioides* the ortholog core of this complex (FvHAP2, FvHAP3, and FvHAP5) is deleted, cells show an altered hyphal morphology, reduction of growth, reduced pathogenesis and a deregulation of secondary metabolism ([@B162]).

#### Specific regulator-based regulation

In addition to the global regulators, the expression of BGCs can be also modulated by specific regulatory elements, which most of the times are encoded by genes that are part of the same cluster that they regulate. In some cases, such regulators also influence the expression of other BGCs. It is estimated that about 60% of the fungal BGCs contain a gene encoding a potential regulator amidst the gene cluster. With PKS containing BGCs mostly containing a regulator that belongs to the Zn~2~Cys~6~ binuclear cluster domain family (around 90%). With NRPS containing BGCs, the putative transcription factors are more diverse. The Zn~2~Cys~6~ family of transcription factors contain a DNA binding domain (DBD) that has two zinc atoms coordinated by six cysteines. There are three sub regions: a linker, a zinc finger and a dimerization domain. Additional to a DBD, these proteins contain two further functional domains, the acidic region and the regulatory domain. These transcription factors can act as monomers, hetero- and homodimers. They recognize single or multiple trinucleotide sequences, commonly CCG triples, in a symmetric or asymmetrical format. The affinity of the DBD for a given DNA stretch is also determined by the nucleotides surrounding this triplet. The transcriptional activity of these proteins is regulated by phosphorylation, exposing the activation and DNA binding domains for DNA binding ([@B124]; [@B27]). Some of these regulators have been shown to control the expression of BGCs. For instance, in *F. verticillioides* the disruption of *FUM21* gene, that encodes a Zn~2~Cys~6~ protein, reduces fumonisin production as a result of a downregulation of the BGC ([@B30]). Interestingly, fumonisin production is also regulated by another Zn~2~Cys~6~ protein that is encoded by a gene located outside of the fumonisin cluster ([@B72]). Mlcr is another example of a positive regulator that controls compactin production in *P. citrum* ([@B1]). AflR is a Zn~2~Cys~6~ protein that regulates the biosynthesis of aflatoxin/sterigmatocystin through binding to a palindromic sequence (5′-TCG(N~5~)GCA) that is found in most of the promoters of this BGC, albeit a second binding sequence has been reported that is associated with the autoregulation mechanism of the expression of *AflR*. The disruption of *AlfR* abolishes the production of aflatoxin/sterigmatocystin. Likewise, some BGCs encode multiple regulatory proteins. Next to the *aflR* gene in the aflatoxin cluster resides the *aflS* (formerly *aflJ*) gene. The corresponding transcription factor binds to AflR to enhance the transcription of early and mid-biosynthetic genes in the aflatoxin pathway ([@B77]; [@B222]). In *P. chrysogenum* and *Trichoderma reesei*, the sorbicillin BGC is regulated by two transcriptional factors through a coordinated action ([@B57], [@B55]; [@B80]). Also, regulation of BGCs via crosstalk has been observed in filamentous fungi. For instance, the alcohol dehydrogenase promoter has been used to induce the expression of putative pathway-specific regulatory gene *(scpR)* in *A. nidulans*, which controls the expression of two pathway associated NRPS genes (*inpA* and *inpB*). Surprisingly, two PKS genes (*afoE* and *afoG*) and one transcriptional activator (*afoA*) belonging to the asperfuranone BGC are also upregulated by ScpR, allowing the production of asperfuranone ([@B19]). For some regulators, no clear phenotype is observed. For instance deletion of the *chyR* gene of the chrysogine BGC in *P. chrysogenum*, has no effect on the expression of the corresponding BGC ([@B201]).

#### Manipulation of regulatory elements as strategies for the activation of BGCs

##### Gene deletion

It is a classical strategy that consists of the abolishment of the expression of a certain gene by its elimination whereupon the impact on the metabolite profile is examined by HPLC or LC-MS. A major limitation of this approach is that it can only be used in BGCs that are not totally silenced under laboratory conditions. Using this strategy, it was possible to elucidate the highly branched biosynthetic pathway for the synthesis of roquefortine as well as the biosynthetic pathways of sorbicillinoids and chrysogine in *P. chrysogenum* ([@B76]; [@B3]; [@B163]; [@B53]; [@B80]; [@B201]). Likewise, this approach can be used to remove transcriptional repressor genes, as in the case of TetR-like pathway-specific repressor proteins, whose deletion induced the production of gaburedins in *Streptomyces venezuelae* ([@B168]). Global regulators, such as LaeA have also been targeted using this strategy ([@B44]).

##### Promoter replacement

Another method concerns the replacement of the endogenous promoter of the gene(s) in a BGC by a strong constitutive or inducible promoter. For instance in *A. nidulans* replacement of the native promotor of the *scpR* gene (secondary metabolism cross-pathway regulator) for the inducible promoter of alcohol dehydrogenase AlcA induced the expression of a silent cluster that contained two NRPS genes (*inpA* and *inpB)* and *scpR* itself. Additionally, it also led to the expression of the asperfuranone BGC, which is normally silent ([@B19]; [@B222]; [@B117]). Recently in *P. chrysogenum* a promising promoter toolbox for bioengineering purposes was developed. This included the analysis of four constitutive promoters from *P. chrysogenum* and six from *A. niger*, which were evaluated using a reporter system and assorted by promoter strength ([@B157]).

##### Overexpression of a specific or global regulator

This approach is one of the most used strategies to turn on cryptic BGCs, since a change in expression level of a regulator may boost the expression of a whole cluster. Usually, this strategy is applied in combination with the *promoter replacement* approach. Using this strategy, i.e., overexpression of the transcription activator ApdR under control of the alcohol dehydrogenase promoter *alcAp*, it has been possible to induce the expression of a hybrid PKS-NRPS BGC in *A. nidulans.* This resulted in the production of aspyridones A and B ([@B20]). Similarly when the global regulator FfSge, which is associated with vegetative growth of *F. fujikuroi*, is overexpressed, some BGCs are forced to express under these unfavorable conditions (low nitrogen concentrations) leading to the identification of the corresponding products ([@B135]).

### Chromatin-Mediated Regulation

In fungal cells, chromosomal DNA is wrapped in a complex of DNA, histone proteins and RNA called chromatin. This chromatin structure consists of a basic unit called nucleosome, which consists of superhelical DNA (147 base pairs) that binds an octamer of four different core histone proteins (two each of H2A, H2B, H3, and H4) in 1.75 turns. It has been shown that modifications of the chromatin structure (boosts or alters) changes gene expression, amongst other genes involved in the biosynthesis of secondary metabolites. Structurally, chromatin represents an obstacle that complicates access of DNA-binding factors to their corresponding binding regions. According to the compaction level, chromatin can be in a dense (heterochromatin) or relaxed (euchromatin) state. These compaction levels are regulated by post-translational modification of the histone proteins by acetylation, methylation, ubiquitination, ethylation, propylation, butylation, and phosphorylation events. Regions that display low transcriptional activity have been associated with the heterochromatic conformation. In contrast, the euchromatic conformation is present in regions with abundant coding sequences and is usually highly active during transcription. Such regions are also linked with hyper-acetylated nucleosomal histones. Likewise, it has been reported that methylation of H3K9, H3K27, and H4K20 are typical markers of the heterochromatin, while in euchromatin methylation occurs at H3K4 ([@B29]; [@B190]; [@B74]; [@B186]; [@B168]).

#### Histone methylation, acetylation, and sumoylation

As mentioned above, LaeA influences secondary metabolite production through chromatin modification. The methylation state of H3K9 has been correlated with the heterochromatin protein A (HepA), since this protein needs the di- and tri- methylation of H3K9 for binding to chromatin and to form heterochromatin. Deletion of LaeA allows the unobstructed binding of HepA to the *AlfR* promoter, thereby affecting the expression of the sterigmatocystin pathway. The deletion of the methyltransferase encoding c*lrD* and *ezhB* genes in *Epichloe festucae*, that act on H3K9 and H3K27, respectively (in axenic culture), results in the activation of the ergot alkaloids and lolitrem BGCs. These compounds are necessary to establish a symbiotic association with the plant *Lolium perenne*. Compass (complex of proteins associated with Set1) which methylates H3K4 in yeast, also impacts secondary metabolism in filamentous fungi. The deletion of one of its components (*cclA*) in *A. nidulans* allowed the activation of a cryptic BGC and the production of emodin ([@B152]; [@B74]; [@B46]; [@B140]; [@B53]). Likewise, in *F. fujikuroi* and *F. graminearum*, the deletion of *cclA* caused the overproduction of secondary metabolites derived from BGCs close to the telomeres, but this seems to relate to a H3K4 methylation independent mechanism ([@B191]). Other types of histone modification may alter the chromatin landscape, such as acetylation which is a reversible process governed by two antagonist enzymes: histone acetyltransferases (HATs) and deacetylases (HDACs). Active transcription is usually associated with histone acetylation, although recently the deacetylation of histones has been shown to cause activation of genes ([@B29]). Usually, histones are acetylated by several complexes with acyltransferase activity, such as Saga/Ada and NuA4. In *A. nidulans* a chromatin immunoprecipitation (ChIP) analysis revealed that GcnE and AdaB, the catalytic subunits of the complex Saga/Ada, are needed for acetylation of histone H3 ([@B53]). Indeed, the interaction between *A. nidulans* and *Streptomyces rapamycinicus* can be linked to a GcnE dependent increase in the acetylation of H3K14 that shields the promoters of the orsellinic acid BGC. The Saga/Ada complex is a key player in the induction of the penicillin, terrequinone and sterigmatocystin BGCs ([@B146]; [@B27]). In contrast, deletion of *hdaA* (encoding a HDAC) in *A. nidulans* resulted in major changes in the metabolite profile ([@B168]). HdaA is a class 2 histone deacetylase involved in the regulation of BGCs that are located near the telomeres, such as the penicillin and sterigmatocystin clusters in *A. nidulans*. Indeed, deletion of the *hdaA* gene results in the increased and early gene expression of these two BGCs, and the production of the corresponding secondary metabolites. In *A. fumigatus*, the *hdaA* gene is involved in growth and production of secondary metabolites, and the deletion of this gene increases the production of many secondary metabolites while it causes a reduction of gliotoxin production. In contrast, HdaA overexpression shows the opposite effect ([@B182]; [@B113]). In *P. chrysogenum* was demonstrated that HdaA (histone deacetylase) mediates the transcriptional crosstalk among sorbicillinoids biosynthesis and other BGCs, since a new compound as detected only under conditions of sorbicillinoids production ([@B81]).

Histone deacetylases are ubiquitously distributed in filamentous fungi, and therefore HDAC inhibitors can be used to improve the synthesis of NPs by epigenome manipulation ([@B182]; [@B113]). For instance, the metabolite profile of *Cladosporium cladosporioides* and *A. niger* underwent a significant change when these strains were exposed to suberoylanilide hydroxamic acid (SAHA), a HDAC inhibitor, allowing the detection of two new compounds, cladochrome and nygerone A, respectively ([@B168]). An exploratory analysis performed in 12 fungi treated with different types of DNA methyltransferase and histone deacetylase inhibitors, revealed the production of new secondary metabolites but also the elevated amounts of known compounds ([@B218]). In this respect, the chromatin state can directly influence the binding of transcription factors, and thereby modulate expression ([@B152]; [@B123]). It has been hypothesized that histone sumoylation may modulate secondary metabolite production. This process is mediated by a small protein termed SUMO (small ubiquitin-like modifier) that shares structural similarity to the ubiquitin protein. In *A. nidulans*, deletion of the *sumO* gene enhanced the production of asperthecin, whereas synthesis of austinol, dehydroaustinol, and sterigmatocystin was reduced. Although the molecular mechanism still needs to be elucidated, it is thought that sumoylation acts at several levels, such as on epigenetic regulators (COMPASS, Clr4, SAGA/ADA and HDACs) or at the level of transcriptional regulators ([@B28]; [@B186]; [@B219]).

#### Modification of the chromatin landscape to activate BGCs

Many fungal BGCs are located in distal regions of the chromosomes. In these heterochromatin rich regions, transcription of the BGCs can be activated by epigenetic regulation. Therefore, the encoding genes of proteins that influence histone modification are prime targets, although these modifications can also be achieved by chemical treatment ([@B218]; [@B27]). A recent study in *P. chrysogenum* showed that the expression of a set of PKS and NRPS encoding genes is induced when an ortholog of a class 2 histone deacetylase (HdaA) is deleted. This allowed for the overproduction of sorbicillinoids, the reduction of chrysogine related metabolites and the detection of a new compound whose origin still unknown ([@B81]).

### Other Targets for Regulation

Secondary metabolites produced by fungi can be toxic to the producer organisms, and often fungi are equipped with detoxification mechanisms. One of these mechanisms is toxin excretion by transporters, which are membrane proteins whose genes often localize to the BGCs. Transporters may belong to different protein families but the major facilitator superfamily (MFS) and ABC superfamily are most commonly encoded by BGCs ([@B103]). Since biosynthesis of secondary metabolites may take place in different cell compartments, also intracellular transport may be evident ([@B107]). Despite their assumed biological importance, the deletion of transporter genes from the BGCs often does not impact secondary metabolite production. For instance, deletion of the *A. parasiticus aflT* gene, that encodes a MFS transporter, does not result in reduced aflatoxin excretion, despite the fact that *aflT* belongs to the aflatoxin BGC and its expression is regulated by a specific transcription factor, AflR, of the pathway. Probably, this protein is redundant, and other transporters may participate in excretion, detoxification or self-defense. In *A. fumigatus*, GliA facilitates the excretion of gliotoxin. Similarly, the *tri12* gene contained in the trichothecene BGC encodes for a membrane protein required for the biosynthesis of trichothecene and virulence of *F. graminearum* on wheat crops ([@B41]; [@B134]; [@B204]; [@B103]). Often, however, the deletion of the transporter gene in BGCs has no effect on production. Possibly, these metabolites are also recognized by other promiscuous transporters, or transporters that are not part of the BGC ([@B103]). For example, ZRA1 of *Gibberella zae*, whose gene is not localized to the zearalenona BGC, impacts zearalenone production. However, the expression of the *zra1* gene is regulated by the transcriptional factor ZEB2, whose gene localizes to the corresponding BGC ([@B114]). Also, the penicillin BGC of *P. chrysogenum* lacks a transporter gene whereas export of penicillin occurs against the concentration gradient, probably through the activity of multiple transporter proteins ([@B200]; [@B107]). Furthermore, compartmentalization of the biosynthesis of penicillin is well documented requiring transport of penicillin precursors across the membrane of intracellular organelles ([@B210],[@B211]).

### Other Genetic Engineering Strategies for the Activation of BGCs

Several approaches have been used to activate the expression of cryptic BGCs in a targeted manner. Usually, this is achieved by manipulation of pathway-specific regulatory genes, or by replacing endogenous promoters for inducible systems or strong promoters ([@B168]). The various approaches are summarized in Figure [7](#F7){ref-type="fig"}.

#### Manipulating biosynthetic pathways by genome editing

Due to the increasing number of sequenced filamentous fungi, it is necessary to make use of efficient genome editing tools to explore new potential sources of secondary metabolites. For many years, the unique strategy available for the genome edition of *P. chrysogenum* was based on the use of ku70/80 disrupted strains to improve the homologous recombination instead of the Non-Homologous End Joining (NHEJ) pathway ([@B210]). This strategy allowed for the generation *P. chrysogenum* strains with high copy numbers of the penicillin cluster, the identification of a biosynthetic branch of the roquefortine cluster and the reactivation of the sorbicillinoid gene cluster ([@B145]; [@B76]; [@B3]; [@B163]; [@B171]; [@B80]). Recently, a CRISPR/Cas9 based system was developed for genome modifications in *P. chrysogenum* ([@B155], [@B156]). This study demonstrated that the deletion of full gene clusters is feasible with minimal cloning efforts, which opens the possibilities to engineer new synthetic pathways and the re-factoring *P. chrysogenum* as platform organism.

#### Ribosome engineering

This approach has been applied for activating silent or poorly expressed BGCs ([@B147]). Basically, this concept is derived from the activation of the actinorhodin BGC in *S. lividans* due to a point mutation in the *rpsL* gene, which encodes for the ribosomal S12 protein ([@B181]). Another successful examples in the BGCs activation have been reported by modifying the transcription and translation pathways via targeting different ribosomal proteins, RNA polymerases (RNAP) and translation factors ([@B147]). In *P. purpurogenum* G59, a marine derived strain, the insertion of gentamicin resistance after treatment with high concentrations of this antibiotic, altered ribosomal functions of this fungus which allowed for the activation of dormant secondary metabolite gene clusters ([@B39]).

#### Heterologous expression and refactoring

Due to the broad range of molecular tools available to express heterologous pathways in yeast, several attempts have been undertaken to express NRPS and PKS genes with the remainder of the pathway in yeast ([@B168]). A recent study demonstrated that the baker's yeast *Saccharomyces cerevisiae* can be used as a platform to produce and secrete penicillin when the biosynthetic genes are expressed in this organism ([@B9]). Although the first step was performed when the acetyl-CoA:isopenicillin *N* acyltransferase (IAT), which catalyzes the last step in the penicillin biosynthesis was amplified from the *P. chrysogenum penDE* gene and expressed in *Hansenula polymorpha* ([@B122]). However, most of the times the main obstacle is the large size (\>40 kbp) of the DNA fragment that needs to be cloned, the effective activation/maturation of the expressed enzymes, and the toxicity of the produced compounds ([@B168]). Alternatively, fungi may be used as platform organism, as it was for instance demonstrated with the reconstruction of the citrinin gene cluster of *Monascus purpurea* in *A. oryzae* ([@B186]). Likewise, the *in vivo* assembly of genetic elements has been successfully applied in *P. chrysogenum* through the overlapping of bi-partite fragments that reconstituted a functional *amdS* gene (marker), which eventually is integrated in the genome of this fungus proving the uncharacterized potential of *P. chrysogenum* as heterologous host ([@B157]). The potential of this approach follows a recent study employing *A. nidulans* as a host for the plasmid based expression of a diverse range of BGCs from other filamentous fungi ([@B47]).

The introduction of revolutionary new genetic tools, such as CRISPR/Cas9 offers more effective solutions to express specific BGCs. Such methods can contribute to product identification but also to the production of unique compounds by introduction of specific tailoring enzymes. These are the main strategies that are used for the activation of silent BGCs or for the modification/redirection of known biosynthetic pathways in order to increase NP diversification ([@B183]). Specifically, this involves the expression of pathways from a plasmid in a suitable production host and a screen for product formation.

Concluding Remarks
==================

For many years *P. chrysogenum* has been used as one of the main industrial strains to produce penicillins (β-lactams). Its genome sequence revealed an unexplored potential of *P. chrysogenum* as a source of NPs ([@B200]). Despite the development of bioinformatics tools for genome mining of BGCs to identify novel molecules ([@B21]), the experimental validation of product structure and identity is still necessary. However, most of the secondary metabolite associated genes in *P. chrysogenum* are silent or poorly expressed. Given the urgent need for new molecules based on novel chemical scaffolds for the use in the medical and biotechnological fields (e.g., antibiotics, anti-cancer agents, antivirals, nutraceuticals, pigments, surfactants and many more), the use of organisms that have been genetically domesticated offers a promising target solution for NP discovery due to the availability of molecular tools for their genetic modification. Here, we have summarized the main approaches that have been applied for *P. chrysogenum* and other filamentous fungi to bioengineer secondary metabolite BGC pathways which have led to a greater understanding of the main obstacles to be overcome to use this fungus as a generic cell factory. We discussed the main characteristics of the building enzymes (PKS and NRPS) in filamentous fungi. Despite the apparent modular organization, the complexity of these mega enzymes and the inherent interactions between the various domains within their structures has not allowed a straight forward approach for the PKS/NRPS engineering ([@B197]; [@B227]; [@B215]). However, the combinatorial swapping strategy of structural elements such as recognition regions has increased the perspectives for designing *de novo* biosynthetic pathways. Further research needs to be focused around PKS/NRPS engineering in filamentous fungi to facilitate the rational design of biosynthetic enzymes to produce another generation of novel compounds. To mine the secondary metabolome of filamentous fungi, general methods such as manipulating cultivation conditions have been used that can also be implemented as a high-throughput strategy. Another avenue is interfering with the genetic regulatory systems, either through the manipulation of specific or global regulators. This strategy also revealed crosstalk between certain BGCs and an important role of chromatin remodeling in BGC expression. Because of its pleiotropic effect that leads to the activation or silencing of biosynthetic pathways, chromatin remodeling might be used as a more general strategy to explore the production of new metabolites in filamentous fungi ([@B81]).

A further major advance is the development of genome-editing tools that allow for efficient genetic engineering of complex fungal cell factories ([@B95]). In *P. chrysogenum*, improved methods for homologous recombination and CRISPR/Cas9 as genome editing tool now facilitates more advanced engineering of this fungus ([@B155], [@B156]). This is further stimulated by the development of a synthetic biology toolbox using promoters and terminators as building blocks and more complex regulatory devices to control the expression of genes. Importantly, the *in vivo* assembly of genetic elements in *P. chrysogenum* offers a promising tool to build entire pathways from scratch with reducing cloning efforts at minimal costs ([@B157]). In particular the low cost of DNA synthesis will allow rapid progress using such approaches as exemplified by a study using *A. nidulans* as a host where a diverse set of BGCs was expressed from an extra-chromosomal vector, the AMA plasmid ([@B47]). A further challenge is the generation of a platform strain in which endogenous BGCs have been removed to allow for more optimal carbon and nitrogen flow toward the production of the compounds of interest. Herein, the CRISPR/Cas9 based methods are instrumental ([@B155], [@B156]). Such a *Penicillium* platform might be used as a heterologous host to express a vast arsenal of BGCs from others filamentous fungi and represents a good alternative to yeast as expression host, an organism that does not naturally produce NRP and PK. The use of a such industrial strains to rapidly achieve the high level production of a novel metabolite has proven to be successful for pravastatin production ([@B130]) but a further step is to make use of secondary metabolite deficient industrial strains.

Despite the progress in genetic engineering and bioinformatics tools to identify BGCs, the main bottleneck to identify potentially interesting compounds has not yet been solved. Bioinformatic tools perform poorly in the prediction of the structures formed, and therefore future discovery programs will mostly dependent on high throughput methods to express foreign pathways and then use advanced metabolomics to identify the novel products. Since such approaches depend on high throughput, further efforts are needed to implement high throughput cloning methods to *P. chrysogenum* which will enable further studies to harness the enormous untapped source for NPs hidden in fungal (meta-)genomes.
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